Granted Patent
B2
US 12,544,332 · App. 17/702,608 · Granted Feb 10, 2026
Lipid vesicle compositions with penetration enhancing agents
Assignee:
DDS RESEARCH INC.
A61K9/127A61K8/14A61K9/0014A61K9/1273A61K47/10A61K47/14A61K47/186A61K47/22A61K47/24A61P17/00A61Q19/08
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present application is related to a pharmaceutical composition a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more surfactants; one or more compounds; and one or more penetration enhancing agents. The one or more penetration enhancing agents include one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, alone or combination with one or more penetration enhancing agents selected from one or more of terpenes, alkaloids, salicylate derivatives, and polycationic surfactants and combinations thereof. The present application is also related to a pharmaceutical composition comprising a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more polycationic surfactants; and one or more compounds.
Claims (23)
1 . A biphasic lipid vesicle composition comprising lipid vesicles, wherein a lipid vesicle comprises:
a. a plurality of lipid bilayers comprising vesicle forming lipids;
b. an oil-in-water emulsion entrapped in the lipid vesicle;
c. one or more compounds entrapped in the plurality of lipid bilayers, the oil-in-water emulsion, or both; and
d. at least three non-ionic surfactants comprising:
i. a first surfactant comprising diethylene glycol monooleyl ether, sorbitan monopalmitate, or polyoxyethylene (4) dilaurate;
ii. a second surfactant comprising a hydrophilic-lipophilic balance (HLB) of 10 or less, wherein the first surfactant and the second surfactant are different; and
iii. a third surfactant having an HLB of greater than 10, wherein the third surfactant comprises polyoxyethylene (10) cetyl ether or polysorbate 80.
2 . The composition of claim 1 , wherein the biphasic lipid vesicle composition is for topical delivery of the one or more compounds.
3 . The composition of claim 1 , wherein the biphasic lipid vesicle composition comprises a suspension of the lipid vesicles.
4 . The composition of claim 1 , wherein the second surfactant comprises a polyethylene glycol ether of a fatty alcohol, a sorbitan ester, a polysorbate, or a polyethylene glycol fatty acid ester.
5 . The composition of claim 4 , wherein the polyethylene glycol ether of a fatty alcohol comprises diethylene glycol hexadecyl ether, 2-(2-octadecoxyethoxy)ethanol, polyoxyethylene (3) oleyl ether, and polyoxyethylene (5) oleyl ether, or any combination thereof.
6 . The composition of claim 4 , wherein the polyethylene glycol fatty acid ester comprises PEG-8 dilaurate, PEG-4 laurate, PEG-8 dioleate, PEG-8 distearate, PEG-7 glyceryl cocoate, PEG-20 almond glyceride, or any combination thereof.
7 . The composition of claim 1 , wherein the composition further comprises one or more terpenes, alkaloids, polycationic surfactants, or any combination thereof.
8 . The composition of claim 7 , wherein the one or more terpenes comprise one or more of eugenol, d-limonene, menthol, menthone, farnesol, nerolidol, camphor, nerol, thymol, or any combinations thereof.
9 . The composition of claim 1 , wherein the composition further comprises ethyl salicylate, salicylic acid, acetylsalicylic acid, trolamine salicylate, or any combination thereof.
10 . The composition of claim 7 , wherein the one or more alkaloids comprise piperine, lobeline, caffeine, theobromine, theophylline, nicotine, colchicine, N-methyl pyrrolidone, hygrine, capsaicin, berberine, sanguinarine, histamine, pilocarpine, or any combination thereof.
11 . The composition of claim 7 , wherein the one or more polycationic surfactants are one or more gemini cationic surfactants and the one or more gemini cationic surfactants are of a quaternary ammonium type.
12 . The composition of claim 7 , wherein the one or more polycationic surfactants are polycationic amino acids.
13 . The composition of claim 1 , wherein the third surfactant stabilizes the oil-in-water emulsion of the biphasic lipid vesicles.
14 . The composition of claim 1 , wherein the vesicle forming lipids comprise one or more of phospholipids, glycolipids, lecithins, ceramides, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid, cerebroside, or any combination thereof.
15 . The composition of claim 1 , wherein the one or more compounds comprise small molecules, proteins, peptides, carbohydrates, nucleic acids, vaccine antigens, plant extracts, or any combination thereof.
16 . The composition of claim 1 , wherein the second surfactant comprises diethylene glycol hexadecyl ether, 2-(2-octadecoxyethoxy) ethanol, polyoxyethylene (3) oleyl ether, polyoxyethylene (5) oleyl ether, polyoxyethylene (4) sorbitan monostearate, sorbitan monolaurate, sorbitan monostearate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, sorbitan isostearate, PEG-8 dilaurate, PEG-4 dilaurate, PEG-8 dioleate, PEG-8 distearate, PEG-7 glyceryl cocoate, PEG-20 almond glycerides, propylene glycol isostearate, glycol stearate, glyceryl stearate, glyceryl laurate, glyceryl caprylate, PEG-30 dipolyhydroxy-stearate, or glycol distearate.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 14, 2023
From: FOLDVARI, MARIANNA
To: DDS RESEARCH INC.
Reel/Frame 064902/0198 →
Continuity (4)
Continuation
PCTCA2020051275
· Sep 23, 2020
Provisional Application
62904606
· Sep 23, 2019
Provisional Application
62904584
· Sep 23, 2019
References Cited (212)
US 4372977A
· Lover et al.
· 1983
[cited by applicant]
US 4855090A
· Wallach
· 1989
[cited by applicant]
US 4968450A
· Kamegai et al.
· 1990
[cited by applicant]
US 5804216A
· Terren et al.
· 1998
[cited by applicant]
US 5846514A
· Foster et al.
· 1998
[cited by applicant]
US 5853755A
· Foldvari
· 1998
[cited by examiner]
US 5993851A
· Foldvari
· 1999
[cited by examiner]
US 5993852A
· Foldvari
· 1999
[cited by examiner]
US 6334997B1
· Foster et al.
· 2002
[cited by applicant]
US 6656499B1
· Foldvari
· 2003
[cited by examiner]
US 6696424B1
· Wheeler
· 2004
[cited by applicant]
US 20030119774A1
· Foldvari et al.
· 2003
[cited by applicant]
US 20040219232A1
· Lipton
· 2004
[cited by applicant]
US 20060040354A1
· O'Keefe
· 2006
[cited by applicant]
US 20080008747A1
· Royds
· 2008
[cited by applicant]
US 20080119433A1
· Tabor
· 2008
[cited by applicant]
US 20090081142A1
· Omura et al.
· 2009
[cited by applicant]
US 20090098171A1
· Alard et al.
· 2009
[cited by applicant]
US 20090297592A1
· Sakuraba
· 2009
[cited by examiner]
US 20100166689A1
· Waugh
· 2010
[cited by applicant]
US 20110268812A1
· Cauchard et al.
· 2011
[cited by applicant]
US 20130224283A1
· Foldvari et al.
· 2013
[cited by applicant]
US 20160151283A1
· Manca et al.
· 2016
[cited by applicant]
US 20170304232A1
· Khan et al.
· 2017
[cited by applicant]
US 20180360757A1
· Doroudian et al.
· 2018
[cited by applicant]
US 20230143474A1
· Foldvari
· 2023
[cited by applicant]
US 20230157954A1
· Foldvari
· 2023
[cited by applicant]
US 20230270635A1
· Love et al.
· 2023
[cited by applicant]
US 20240122823A1
· Foldvari
· 2024
[cited by applicant]
US 20240139089A1
· Love et al.
· 2024
[cited by applicant]
US 20240189231A1
· Foldvari
· 2024
[cited by applicant]
US 20250026787A1
· Love
· 2025
[cited by applicant]
CA 2168260C
· 2000
[cited by applicant]
CA 2324403A1
· 2000
[cited by applicant]
CA 2458443A1
· 2003
[cited by applicant]
CA 3155131A1
· 2021
[cited by applicant]
CN 108778244A
· 2018
[cited by applicant]
CN 108948151A
· 2018
[cited by applicant]
EP 0711148A1
· 1996
[cited by applicant]
EP 2498792A1
· 2012
[cited by applicant]
FR 2816577A1
· 2002
[cited by applicant]
FR 2846238A1
· 2004
[cited by applicant]
FR 2876577A1
· 2006
[cited by applicant]
JP 2001514212A
· 2001
[cited by applicant]
JP 2009515579A
· 2009
[cited by applicant]
JP 2010522698A
· 2010
[cited by applicant]
JP 2019510215A
· 2019
[cited by applicant]
KR 100748035B1
· 2007
[cited by applicant]
KR 20080088888A
· 2008
[cited by applicant]
WO WO9503787A1
· 1995
[cited by applicant]
WO WO9911247A1
· 1999
[cited by applicant]
WO WO0130808A1
· 2001
[cited by applicant]
WO WO0135998A1
· 2001
[cited by applicant]
WO WO2006012414A2
· 2006
[cited by applicant]
WO WO2006116156A2
· 2006
[cited by applicant]
WO WO2008119160A1
· 2008
[cited by applicant]
WO WO2011060083A1
· 2011
[cited by applicant]
WO WO2015023601A1
· 2015
[cited by applicant]
WO WO2018144093A2
· 2018
[cited by applicant]
WO WO2018213932A1
· 2018
[cited by applicant]
WO WO2020081583A1
· 2020
[cited by applicant]
WO WO2021056106A1
· 2021
[cited by applicant]
WO WO2021216572A1
· 2021
[cited by applicant]
WO WO2022204287A1
· 2022
[cited by applicant]
WO WO2022204305A2
· 2022
[cited by applicant]
WO WO2022204308A1
· 2022
[cited by applicant]
WO WO2022204309A1
· 2022
[cited by applicant]
WO WO2023081259A2
· 2023
[cited by applicant]
Som et al (J Pharm Bioallied Sci, 2012, vol. 4, pp. 2-9) (Year: 2012).
[cited by examiner]
Dragicevic et al (Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement, Springer, 2015, pp. 253, 255-256, 258, 259, 260, 263, 264, 265, 266, 267) (Year: 2015).
[cited by examiner]
Becker (Cosmetic Ingredient Review, Safety Assessment of PEG-Distearates as used in cosmetics, Feb. 2015, 36 pages) (Year: 2015).
[cited by examiner]
Sakdiset et al (Chem Pharm Bull., 2017, vol. 65, pp. 776-783) (Year: 2017).
[cited by examiner]
Sekhon (Journal of Pharmaceutical Technology, 2013, vol. 1, pp. 43-68) (Year: 2013).
[cited by examiner]
Kirby et al.: Gemini surfactants: new synthetic vectors for gene transfection. Angew Chem Int Ed Engl. 42(13):1448-1457 (2003).
[cited by applicant]
Lane. Skin penetration enhancers. Int. J. Pharm. 447(1-2):12-21 (2013).
[cited by applicant]
Lotioncrafter. Lotioncrafter.com. Sorbitan Stearate Product Info. Sep. 20, 2020 [retrieved May 18, 2022] https://webarchive.org/web/20200920113912/https://lotionlcrafter.com/products/sorbitan-stearate [entire document].
[cited by applicant]
Menger et al.: Gemini Surfactants. Angew Chem Int Ed Engl. 39(11):1906-1920 (2000).
[cited by applicant]
PCT/CA2020/051275 International Search Report and Written Opinion dated Dec. 21, 2020.
[cited by applicant]
PCT/US2022/021554 International Search Report and Written Opinion dated Jun. 10, 2022.
[cited by applicant]
PCT/US2022/021579 Invitation to Pay Additional Fees dated Jul. 22, 2022.
[cited by applicant]
PCT/US2022/021585 International Search Report and Written Opinion dated Jul. 7, 2022.
[cited by applicant]
U.S. Appl. No. 17/841,924 Office Action dated Aug. 1, 2022.
[cited by applicant]
Williams et al.: Penetration Enhancers. Advanced Drug Delivery Reviews. 64:128-137 (2012).
[cited by applicant]
Zasada et al.: The assessment of the effect of a cosmetic product brightening the skin of people with discolorations of different etiology. Journal of Cosmetic Dermatology. 15:493-502 (2016).
[cited by applicant]
Dhamecha: Drug Vehicle Based Approaches of Penetration Enhancement. 1(1):24-46 (2009).
[cited by applicant]
Gupta et al.: Biocompatible Micro emulsions and Their Prospective Uses in Drug Deliver. Journal of Pharmaceutical Sciences. 97(1):22-45. (2008).
[cited by applicant]
Otto et al.: Formulation effects of topical emulsions on transdermal and dermal delivery. International Journal of Cosmetic Science. 31:1-19 (2009).
[cited by applicant]
Paliwal et al.: Pharmaceutical Considerations of Microemulsion as a Drug Delivery System. Journal of Drug Delivery & Therapeutics. 9(4-s):661-665 (2019).
[cited by applicant]
Talegoankar et al.: Microemulsions: A Novel Approach to Enhanced Drug Delivery. Recent Patents on Drug Delivery & Formulation. 2:238-257 (2008).
[cited by applicant]
Van Staden: Development of topical-transdermal self-emulsifying drug delivery systems. Sci. Pharm. 88:17 (2020).
[cited by applicant]
Zhou et al.: Nano-formulations for transdermal drug delivery: A review. Chinese Chemical Letters. 29:1713-1724 (2018).
[cited by applicant]
Co-pending U.S. Application No. 202318150144, inventor Foldvari; Marianna, filed on Jan. 4, 2023.
[cited by applicant]
Co-pending U.S. Application No. 202318150145, inventor Foldvari; Marianna, filed on Jan. 4, 2023.
[cited by applicant]
Lichtenberg et al.: The Mechanism of Detergent Solubilization of Lipid Bilayers. Biophysical Journal. 105:289-299 (2013).
[cited by applicant]
McClements: Nanoemulsions versus microemulsions: terminology, differences, and similarities. Soft Matter. 8:1719-1729 (2012).
[cited by applicant]
PCT/US2022/021579 International Search Report and Written Opinion dated Oct. 5, 2022.
[cited by applicant]
U.S. Appl. No. 17/841,924 Final Office Action dated Nov. 17, 2022.
[cited by applicant]
Abdulbaqi et al.: Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials. Int J Nanomedicine. 11:2279-2304 (2016).
[cited by applicant]
Albuquerque, Edson et al. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev vol. 89,1: 73-120 (2009).
[cited by applicant]
Aulton's Pharmaceutical, The Design and Manufacture of Medicines. Fourth Edition. p. 442-449 (2021).
[cited by applicant]
Badenhorst et al.: Pharmaceutical Strategies for the Topical Dermal Delivery of Peptides/Proteins for Cosmetic and Therapeutic Applications. Austin J Pharmacol. 2(6):1036- 1046 (2014).
[cited by applicant]
Benson et al.: Proteins and peptides: strategies for delivery to and across the skin. J Pharm Sci. 97(9):3591-3610 (2008).
[cited by applicant]
Berge, Stephen M. et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (1977).
[cited by applicant]
Bos et al.: The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 9(3):165-169 (2000).
[cited by applicant]
Bravo et al.: Benefits of topical hyaluronic acid for skin quality and signs of skin aging: From literature review to clinical evidence. Dermatol Ther. 35(12):e15903 (2022).
[cited by applicant]
Bukhari et al.: Hyaluronic acid, a promising skin rejuvenating biomedicine: A review of recent updates and pre-clinical and clinical investigations on cosmetic and nutricosmetic effects. Int J Biol Macromol. 120(Pt B):1…
[cited by applicant]
Bundgard, Hans., Design of Prodrugs. Elsevier, Amsterdam:1-30 (1985).
[cited by applicant]
Chinese Patent Application No. 2020800813833 First Office Action dated Apr. 27, 2023.
[cited by applicant]
Co-pending U.S. Appl. No. 18/470,334, inventor Foldvari; Marianna, filed Sep. 19, 2023.
[cited by applicant]
Czekalla et al.: Noninvasive Determination of Epidermal and Stratum Corneum Thickness in vivo Using Two-Photon Microscopy and Optical Coherence Tomography: Impact of Body Area, Age, and Gender. Skin Pharmacol Physiol. 3…
[cited by applicant]
Dean, Dennis C. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. Current Pharmaceutical Design 6:1-2 (2000).
[cited by applicant]
Dekan, Zoltan et al. α-Conotoxin Iml incorporating stable cystathionine bridges maintains full potency and identical three-dimensional structure. J Am Chem Soc vol. 133,40: 15866-15869 (2011).
[cited by applicant]
Demarco, Steven et al. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Bioorganic & Medicinal Chemistry vol. 14,24: 83…
[cited by applicant]
European Patent Application No. 4034087A1 Search Report dated Sep. 27, 2023.
[cited by applicant]
Evans, Anthony E. Synthesis of Radiolabeled Compounds. Journal of Radioanalytical and Nuclear Chemistry 64(1-2):9-32 (1981).
[cited by applicant]
Falla et al: Cosmeceuticals and peptides. Clinics in Dermatology 27:485-494 (2009).
[cited by applicant]
Fallacara et al.: Hyaluronic Acid in the Third Millennium. Polymers (Basel). 10(7):701 (2018).
[cited by applicant]
Foldvari et al.: Biphasic vesicles for topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections. Curr Drug Deliv. 8(3):307-319 (2011).
[cited by applicant]
Foldvari et al.: Gene delivery into human skin in vitro using biphasic lipid vesicles. Curr Drug Deliv.3(1):89-93 (2006).
[cited by applicant]
Foldvari et al.: Permeation enhancement by molecular organization switching (MOS): Biphasic vesicles for the cutaneous delivery of proteins. In: Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhance…
[cited by applicant]
Foldvari et al.: Perspectives on Using Nanoscale Delivery Systems in Dermatological Treatment. Current Dermatology Reports. 4(1):1-7 (2015).
[cited by applicant]
Foldvari et al.: Topical Delivery of Interferon Alpha by Biphasic Vesicles: Evidence for a Novel Nanopathway across the Stratum Corneum. Molecular Pharmaceutics. 7(3):751-762 (2010).
[cited by applicant]
Foldvari M. Biphasic vesicles: a novel topical drug delivery system. J Biomed Nanotechnol. 6(5):543-557 (2010).
[cited by applicant]
Folvari: Observations of membrane fusion in a liposome dispersion: the missing fusion intermediate? F1000 Research. 4(4):1-11 (2015).
[cited by applicant]
Griffin, William et al. “HLB” or “Hydrophilic-Lipophilic Balance” value refers to standard HLB. Official Journal of the Society of Cosmetic Chemists vol. 5,4: 249-256 (1954).
[cited by applicant]
Handbook of Pharm Excipients—Glyceryl Monostearate (sixth edition) p. 290-293 (2009).
[cited by applicant]
Higuchi, T. et al. Pro-drugs as Novel Delivery Systems, vol. 14 of the A.C.S. Symposium Series and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press (1…
[cited by applicant]
Horrell et al.: Melanocortin 1 Receptor: Structure, Function, and Regulation. Frontiers in Genetics 7(95):1-16 (2016).
[cited by applicant]
Huzil et al.: Drug delivery through the skin: molecular simulations of barrier lipids to design more effective noninvasive dermal and transdermal delivery systems for small molecules, biologics, and cosmetics. Wiley Int…
[cited by applicant]
Iaconisi et al.: Hyaluronic Acid: A Powerful Biomolecule with Wide-Ranging Applications—A Comprehensive Review. Int J Mol Sci. 24(12)(2023).
[cited by applicant]
Jayawickreme et al.: Discovery and Structure-Function Analysis of α-Melanocyte-stimulating Hormone Antagonists. The Journal of Biological Chemistry. 269(47):29846-29854 (1994).
[cited by applicant]
Kabalka, George. W. et al. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates. Tetrahedron 45(21):6601-6621 (1989).
[cited by applicant]
Kalamida, Dimitra et al. Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. The FEBS Journal vol. 274, 15: 3799-3845 (2007).
[cited by applicant]
Kim et al.: A novel dermal delivery system using natural spicules for cosmetics and therapeutics. J Cosmet Dermatol. 21(10):4754-4764 (2022).
[cited by applicant]
Kim et al. Arc-poration improves transdermal delivery of biomolecules. J Cosmet Dermatol. 23(6):2240-2248 (2024).
[cited by applicant]
King et al.: Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther. 4(4):479-488 (2002).
[cited by applicant]
Knerr, Patrick et al. Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin. ACS Chem Biol vol. 6,7: 753-760 (2011).
[cited by applicant]
Koivukangas et al.: Increased collagen synthesis in psoriasis in vivo. Arch Dermatol Res. 287:171-175 (1995).
[cited by applicant]
Kyte et al.: A simple method for displaying the hydropathic character of a protein. Journal of Molecular Biology 157:105-131 (1982).
[cited by applicant]
Lademann et al.: Determination of the thickness and structure of the skin barrier by in vivo laser scanning microscopy. Laser Phys Lett. 5(4):311-315n (2008).
[cited by applicant]
Lee et al.: Laser-assisted nanoparticle delivery to promote skin absorption and penetration depth of retinoic acid with the aim for treating photoaging. Int J Pharm. 627:122162 (2022).
[cited by applicant]
Liatsopoulou et al.: Iontophoresis in dermal delivery: A review of applications in dermato-cosmetic and aesthetic sciences. Int J Cosmet Sci. 2023;45(2):117-132 (2023).
[cited by applicant]
Lv et al.: Collagen-Based Dissolving Microneedles with Flexible Pedestals: A Transdermal Delivery System for Both Anti-Aging and Skin Diseases. Adv Healthc Mater. 12(21):e2203295 (2023).
[cited by applicant]
Makino et al.: Evaluation of a Hydroquinone-free Skin Brightening Product Using in Vitro Inhibition of Melanogenesis and Clinical Reduction of Ultraviolet-induced Hyperpigmentation. Journal of Drugs in Dermatology 12:s1…
[cited by applicant]
McNulty et al.: Structures of the Agouti Signaling Protein. Journal of Molecular Biology 346:1059-1070 (2005).
[cited by applicant]
Moghadam et al.: Effect of Chemical Permeation Enhancers on Stratum Corneum Barrier Lipid Organizational Structure and Interferon Alpha Permeability. Molecular Pharmaceutics. 10:2248-2260 (2013).
[cited by applicant]
Mortazavi et al.: Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci. 44(2):232-248 (2022).
[cited by applicant]
Nguyen, Giang et al. Making circles: recent advance in chemical and enzymatic approaches in peptide macrocyclization. Journal of Biochemistry and Chemical Sciences vol. 1,1: 1-13 (2017).
[cited by applicant]
Nix et al.: Molecular and Functional Analysis of Human β-Defensin 3 Action at Melanocortin Receptors. Chem Biol. 20(6):784-795 (2013).
[cited by applicant]
Papakonstantinou E, Roth M, Karakiulakis G. Hyaluronic acid: A key molecule in skin aging. Dermatoendocrinol. 4(3):253-258 (2012).
[cited by applicant]
PCT/US2022/021554 International Preliminary Report on Patentability dated Oct. 5, 2023.
[cited by applicant]
PCT/US2022/021585 International Preliminary Report on Patentability dated Oct. 5, 2023.
[cited by applicant]
PCT/US2022/048780 International Search Report and Written Opinion dated Apr. 27, 2023.
[cited by applicant]
Rahiman et al.: Novasome: A Pioneering Advancement in Vesicular Drug Delivery. International Journal of Applied Pharmaceutics. 13(1):59-64 (2021).
[cited by applicant]
Salwowska et al.: Physiochemical properties and application of hyaluronic acid: a systematic review. J Cosmet Dermatol. 15(4):520-526 (2016).
[cited by applicant]
Shen et al.: Effect of Nonionic Surfactants on Percutaneous Absorption of Salicylic Acid and Sodium Salicylate in the Presence of Dimethyl Sulfoxide. Journal of Pharmaceutical Sciences. 65(12):1780-1783 (1976).
[cited by applicant]
Shin et al.: Effects of non-ionic surfactants as permeation enhancers towards piroxicam from the poloxamer gel through rat skins. International Journal of Pharmaceutics. 222(2):199-203 (2001).
[cited by applicant]
Shin et al.: Enhanced transdermal delivery of triprolidine from the ethylene-vinyl acetate matrix. European Journal of Pharmaceutics and Biopharmaceutics. 54(3):325-328 (2002).
[cited by applicant]
Spicer, Christopher et al. Selective chemical protein modification. Nature Communications vol. 5:4740, pp. 1-14 (2014).
[cited by applicant]
Tam, James et al. Chemical Synthesis of Circular Proteins. The Journal of Biological Chemistry vol. 287,32: 27020-27025 (2012).
[cited by applicant]
U.S. Appl. No. 17/841,924 Office Action dated Jun. 2, 2023.
[cited by applicant]
U.S. Appl. No. 18/150,144 Office Action dated Apr. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/150,145 Final Office Action dated Sep. 8, 2023.
[cited by applicant]
U.S. Appl. No. 18/150,145 Office Action dated May 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/150,145 Office Action dated May 8, 2023.
[cited by applicant]
U.S. Appl. No. 18/473,073 Office Action dated Jun. 14, 2024.
[cited by applicant]
Website: Emulsifying Agents in Pharmaceuticals. https://pharmaeducation.net/emulsifying-agents/ 11 pages (2023).
[cited by applicant]
Asakawa, Hitoshi, and Fukuma, Takeshi. The molecular-scale arrangement and mechanical strength of phospholipid/cholesterol mixed bilayers investigated by frequency modulation atomic force microscopy in liquid. Nanotechn…
[cited by applicant]
Cullis, Pieter R. et al. Chapter 1: Physical properties and functional roles of lipids in membranes. Biochemistry of Lipids, Lipoproteins and Membranes :1-33 (1996).
[cited by applicant]
EP22776572.4 European Search Report dated Feb. 13, 2025.
[cited by applicant]
EP22776587.2 European Search Report dated Feb. 18, 2025.
[cited by applicant]
EP22890753.1 Extended European Search Report dated Aug. 19, 2025.
[cited by applicant]
European Application No. 22776585.6 Supplementary Partial Search Report mailed Jan. 24, 2025.
[cited by applicant]
Foldvari, Marianna et al. Biphasic vesicles: a novel topical drug delivery system. Journal of biomedical nanotechnology 6(5):543-557 (2010).
[cited by applicant]
Foldvari, Marianna et al. Gene delivery into human skin in vitro using biphasic lipid vesicles. Current Drug Delivery 3(1):89-93 (2006).
[cited by applicant]
Foldvari, Marianna et al. Topical Delivery of Interferon Alpha in Human Volunteers and Treatment of Patients with Human Papillomavirus Infections. Current Drug Delivery 8(3):307-319 (2011).
[cited by applicant]
Hruby: Design of cyclic peptides with biological activities from biologically active peptides: the case of peptide modulators of melanocortin receptors. Biopolymers, John Wiley. 106(6):884-888 (2016).
[cited by applicant]
Ionov, R. et al. Interactions of lipid monolayers with the natural biopolymer hyaluronic acid. Biochimica et Biophysica Acta (BBA)—Biomembranes 1667(2):200-207 (2004).
[cited by applicant]
King, Martin J. et al. Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technology and Therapeutics 4(4):479-488 (2002).
[cited by applicant]
Lacquer Plump. Product Description. CNPD. Mintel. http://www.gnpd.com XP002782678. 1-7 (2008).
[cited by applicant]
Lim, Seng Han. et al. Enhanced skin permeation of anti-wrinkle peptides via molecular modification. Scientific Reports 8(1):1596, 1-11 (2018).
[cited by applicant]
Long et al.: Transdermal delivery of peptide and protein drugs: Strategies, advantages and disadvantages. Journal of drug delivery science and technology. 60(102007):1-16 (2020).
[cited by applicant]
Moradi, Amir. et al. In Vivo and Ex Vivo Evaluation of a Novel Method for Topical Delivery of Macromolecules Through the Stratum Corneum for Cosmetic Applications. Dermatologic surgery 51(4):403-408 (2025). Published on…
[cited by applicant]
Redondo-Morata, Lorena et al. Influence of cholesterol on the phase transition of lipid bilayers: a temperature-controlled force spectroscopy study. Langmuir 28(35):12851-12860 (2012).
[cited by applicant]
Singapore Patent Application No. 11202202816P Search Report dated Mar. 21, 2025.
[cited by applicant]
Soybean Phospholipids and Formulations. Lipoid 2025; [Retrieved on Mar. 11, 2025]. Available at URL:https://lipoid.com/en/products/raw-material-sources/soybean-phospholipids-formulations/ pp. 1-3.
[cited by applicant]
Thirumoorthy et al.: Novel agouti-related-protein-based melanocortin-1 receptor antagonist. Journal of Medicinal Chemistry. American Chemical Society. US. 44(24):4114-4124 (2001).
[cited by applicant]
Uchegbu et al: Non-ionic surfactant based vesicles (niosomes) in drug delivery. International Journal of Pharmaceutics. 172(1-2):33-70 (1998).
[cited by applicant]
U.S. Appl. No. 18/052,490 Office Action dated Mar. 24, 2025.
[cited by applicant]
U.S. Appl. No. 18/431,490 Office Action dated Jul. 28, 2025.
[cited by applicant]
Zhang, Yongtai et al. Co-hybridized composite nanovesicles for enhanced transdermal eugenol and cinnamaldehyde delivery and their potential efficacy in ulcerative colitis. Nanomedicine Nanotechnology Biology and Medicin…
[cited by applicant]